General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-04-25 | 2024-03 | -1.49 | -1.32 | 0.17 | 11.41% |
2024-02-06 | 2023-12 | 1.76 | 1.72 | -0.04 | -2.27% |
2023-11-07 | 2023-09 | 1.91 | 2.29 | 0.38 | 19.90% |
2023-08-03 | 2023-06 | 1.6 | 1.34 | -0.26 | -16.25% |
2023-04-27 | 2023-03 | 1.63 | 1.37 | -0.26 | -15.95% |
2023-02-02 | 2022-12 | 1.5 | 1.67 | 0.17 | 11.33% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | B of A Securities | Upgrade | Neutral | Buy |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-09-05 | HSBC | Upgrade | Reduce | |
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-08-08 | Benchmark | Upgrade | Buy | Buy |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-05-02 | BARTON JACQUELINE K | Director | 22.23K | Stock Award(Grant) |
2024-03-07 | DICKINSON ANDREW D | Chief Financial Officer | 134.98K | Conversion of Exercise of derivative security |
2023-05-02 | LOFTON KEVIN E | Director | 0.00 | Stock Award(Grant) |
2024-02-01 | LOVE TED WENDELL | Director | 512.00 | Stock Award(Grant) |
2024-03-07 | MERCIER JOHANNA | Officer | 118.43K | Conversion of Exercise of derivative security |
2024-03-07 | O'DAY DANIEL PATRICK | Chief Executive Officer | 484.85K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 126.19M | 9.73B | 10.13% |
2023-06-29 | Vanguard Group Inc | 113.37M | 8.74B | 9.10% |
2023-06-29 | Capital World Investors | 80.93M | 6.24B | 6.50% |
2023-06-29 | State Street Corporation | 59.32M | 4.57B | 4.76% |
2023-06-29 | Capital Research Global Investors | 57.90M | 4.46B | 4.65% |
2023-06-29 | Dodge & Cox Inc | 33.98M | 2.62B | 2.73% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 38.97M | 3.00B | 3.13% |
2023-09-29 | Income Fund of America Inc | 34.44M | 2.58B | 2.76% |
2023-06-29 | Vanguard 500 Index Fund | 29.70M | 2.29B | 2.38% |
2023-06-29 | Dodge & Cox Stock Fund | 24.24M | 1.87B | 1.95% |
2023-08-30 | Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF | 21.14M | 1.62B | 1.70% |
2023-09-29 | Washington Mutual Investors Fund | 20.14M | 1.51B | 1.62% |
Dividend | Date |
---|---|
0.77 | 2024-06-14 |
0.77 | 2024-03-14 |
0.75 | 2023-12-14 |
0.75 | 2023-09-15 |
0.75 | 2023-09-14 |
0.75 | 2023-06-14 |
Split | Date |
---|---|
2 : 1 | 2013-01-28 |
2 : 1 | 2007-06-25 |
2 : 1 | 2004-09-07 |
2 : 1 | 2002-03-08 |
2 : 1 | 2001-02-22 |
$GILD Finally getting its due!!!
$GILD Solid support here. Something is going on. Deal in progress?
$GILD I like the action here. Something is going on. Good chart, nice volume. Someone knows something…..
How do you know the significance of a Delta variant ? You don’t ! By CDC’s own admission, (don’t believe me, check their official site, please) , the PCR test which has spooked us all, cannot even differentiate between Covid, Flu let alone some Delta variant and new tests are being released at year-end due to false positives in the historical data base. This is such a con game and we are all victims.
$GILD Buyout, Merge rumors persist. Is it AZ again at a higher price? Is it Roch? Very interesting read.
https://www.griproom.com/fun/it-looks-like-gilead-is-about-to-merge-with-roche
$GILD Something is going on here. Someone knows something.
$GILD Roche buys $GILD for $120???
Very interesting article with facts.
https://www.griproom.com/fun/it-looks-like-gilead-is-about-to-merge-with-roche
$GILD Upgrades and coverage starting. Numerous catalysts ahead. $100 by December
$GILD Oppenheimer started coverage on Gilead Sciences in a research note on Monday, June 28th. They issued a "buy" rating and a $100.00 target price on the stock. Jefferies Financial Group reissued a "buy" rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Friday, May 7th. Morgan Stanley boosted their target price on Gilead Sciences from $81.00 to $83.00 and gave the company an "overweight" rating in a research note on Monday
Gilead has to get into CRISPR. Check out CRBU patents https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=0&f=S&l=50&d=PTXT&RS=AN%2FCaribou&Refine=Refine+Search&Query=AN%2FCaribou+AND+Biosciences
$GILD Come on bitch. Close over $70
$GILD Company Executives need to be higher profile. Get out there and do some press on the company! Lots to talk about. Stop being a boring suit!
$GILD Wall Street brokerages forecast that Gilead Sciences, Inc. (NASDAQ:GILD) will post $6.15 billion in sales for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Gilead Sciences' earnings. The lowest sales estimate is $6.02 billion and the highest is $6.27 billion. Gilead Sciences posted sales of $5.14 billion during the same quarter last year, which suggests a positive year over year growth rate of 19.6%.
25 million worth of calls placed today nice
$GILD Some dammed lousy company. I had been stuck into it for more than one year & finally got out of it today taking some hit in a little over 10k. Thank goodness. I’m out!!!